Literature DB >> 24718843

Cirrhosis and liver failure: expanding phenotype of Acid sphingomyelinase-deficient niemann-pick disease in adulthood.

Olivier Lidove1, Frédéric Sedel, Frédéric Charlotte, Roseline Froissart, Marie T Vanier.   

Abstract

Acid sphingomyelinase-deficient Niemann-Pick disease (ASMD) includes the severe neuronopathic type A, the non-neuronopathic type B, and rare intermediate cases. Here we report on such an atypical type B patient who died at 31 years of age from liver failure. This male subject was first seen in a paediatric department at the age of 3 years because of significant hepatosplenomegaly. Foam cells in bone marrow, interstitial pneumonitis, a slight facial dysmorphy and normal psychomotor development were additional findings. Acid sphingomyelinase studies in lymphocytes (and later SMPD1 gene studies [c.151_154delGACT; c.1341-21_1341-18delAATG]) established the diagnosis of ASMD. Between the ages 6-27, he developed growth retardation, peripheral neuropathy, kyphoscoliosis, alopecia, and aortic valve insufficiency requiring valve replacement. Surgery for bilateral inguinal hernias was performed twice, when the patient was 10 and 21 years of age, respectively. At the age of 28, he was noted to have hepatosplenomegaly and follow-up investigations revealed ascites and gastric varices. Liver biopsy showed cirrhosis without areas of necrosis (A6 in Child-Pugh classification). He developed haematemesis and worsening encephalopathy leading to his death at age 31. In conclusion, cirrhosis should be considered as a possible complication of ASMD in adult patients, even if hepatic tests are normal.

Entities:  

Year:  2014        PMID: 24718843      PMCID: PMC4270874          DOI: 10.1007/8904_2014_306

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  17 in total

1.  Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials.

Authors:  M M McGovern; A Aron; S E Brodie; R J Desnick; M P Wasserstein
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

2.  Heterogeneity of liver disorder in type B Niemann-Pick disease.

Authors:  T Takahashi; K Akiyama; M Tomihara; T Tokudome; F Nishinomiya; Y Tazawa; K Horinouchi; T Sakiyama; G Takada
Journal:  Hum Pathol       Date:  1997-03       Impact factor: 3.466

3.  Acid sphingomyelinase (Asm) deficiency patients in The Netherlands and Belgium: disease spectrum and natural course in attenuated patients.

Authors:  C E M Hollak; E S V de Sonnaville; D Cassiman; G E Linthorst; J E Groener; E Morava; R A Wevers; M Mannens; J M F G Aerts; W Meersseman; E Akkerman; K E Niezen-Koning; M F Mulder; G Visser; F A Wijburg; D Lefeber; B J H M Poorthuis
Journal:  Mol Genet Metab       Date:  2012-06-30       Impact factor: 4.797

4.  Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick disease.

Authors:  Anna Moles; Núria Tarrats; José C Fernández-Checa; Montserrat Marí
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

5.  Sphingosylphosphorylcholine in Niemann-Pick disease brain: accumulation in type A but not in type B.

Authors:  C Rodriguez-Lafrasse; M T Vanier
Journal:  Neurochem Res       Date:  1999-02       Impact factor: 3.996

6.  A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Roberto Giugliani; Bruno Bembi; Marie T Vanier; Eugen Mengel; Scott E Brodie; David Mendelson; Gwen Skloot; Robert J Desnick; Noriko Kuriyama; Gerald F Cox
Journal:  Pediatrics       Date:  2008-07-14       Impact factor: 7.124

7.  Cirrhosis and portal hypertension in a patient with adult Niemann-Pick disease.

Authors:  J P Tassoni; K A Fawaz; D E Johnston
Journal:  Gastroenterology       Date:  1991-02       Impact factor: 22.682

8.  Fatal liver failure in two children with Niemann-Pick disease type B.

Authors:  P Labrune; P Bedossa; P Huguet; F Roset; M T Vanier; M Odievre
Journal:  J Pediatr Gastroenterol Nutr       Date:  1991-07       Impact factor: 2.839

Review 9.  The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease.

Authors:  E H Schuchman
Journal:  J Inherit Metab Dis       Date:  2007-07-12       Impact factor: 4.982

10.  The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study.

Authors:  Melissa P Wasserstein; Robert J Desnick; Edward H Schuchman; Sabera Hossain; Sylvan Wallenstein; Carin Lamm; Margaret M McGovern
Journal:  Pediatrics       Date:  2004-11-15       Impact factor: 7.124

View more
  5 in total

1.  Acid Sphingomyelinase Inhibition Prevents Development of Sepsis Sequelae in the Murine Liver.

Authors:  Ha-Yeun Chung; C Julius Witt; Nayla Jbeily; Jorge Hurtado-Oliveros; Benjamin Giszas; Amelie Lupp; Markus H Gräler; Tony Bruns; Andreas Stallmach; Falk A Gonnert; Ralf A Claus
Journal:  Sci Rep       Date:  2017-09-27       Impact factor: 4.379

Review 2.  Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD).

Authors:  Margaret M McGovern; Ruzan Avetisyan; Bernd-Jan Sanson; Olivier Lidove
Journal:  Orphanet J Rare Dis       Date:  2017-02-23       Impact factor: 4.123

3.  Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency.

Authors:  David Cassiman; Louis Libbrecht; Wouter Meersseman; Alexander Wilmer
Journal:  Case Rep Gastrointest Med       Date:  2019-04-04

4.  Clearance of Hepatic Sphingomyelin by Olipudase Alfa Is Associated With Improvement in Lipid Profiles in Acid Sphingomyelinase Deficiency.

Authors:  Beth L Thurberg; Melissa P Wasserstein; Simon A Jones; Thomas D Schiano; Gerald F Cox; Ana Cristina Puga
Journal:  Am J Surg Pathol       Date:  2016-09       Impact factor: 6.394

Review 5.  Lysosomal and Mitochondrial Liaisons in Niemann-Pick Disease.

Authors:  Sandra Torres; Elisa Balboa; Silvana Zanlungo; Carlos Enrich; Carmen Garcia-Ruiz; Jose C Fernandez-Checa
Journal:  Front Physiol       Date:  2017-11-30       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.